SCHEMBL128368

SCHEMBL128368

CCCCCC(=O)OCc1ccc(O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 7/20 0.54
DGKA P23743 1/20 0.52
ESR1 P03372 3/20 0.50
ADRA2A P08913 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
TACR2 P21452 2/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
SHBG P04278 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
HSPD1 P10809 1/20 0.50
ADRB3 P13945 1/20 0.50
HTR2C P28335 1/20 0.50
HSPE1 P61604 1/20 0.50
HIF1A Q16665 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31331684 0.98 HSD17B3 (0.56) HSD17B3DGKAESR1ADRA2AADORA3
SCHEMBL125475 0.98 HSD17B3 (0.56) HSD17B3DGKAESR1ADRA2AADORA3
SCHEMBL3814877 0.93 DGKA (0.60) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL5709846 0.88 ALDH1A1 (0.51) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL4206910 0.88 DGKA (0.55) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL4207553 0.88 DGKA (0.55) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL18087035 0.88 DGKA (0.55) DGKALMNAALDH1A1ELANEMEN1
SCHEMBL4219075 0.88 DGKA (0.55) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL4212801 0.88 DGKA (0.55) DGKALMNAKDM4EALDH1A1ELANE
SCHEMBL4211547 0.88 DGKA (0.55) DGKALMNAKDM4EALDH1A1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108770357-A Polymer combined vaccine 芝加哥大学 2018-11-06 CN disclosed
EP-2428577-B1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters EASTMAN CHEM CO (US) 2014-01-22 EP disclosed
EP-2428577-A1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters EASTMAN CHEMICAL COMPANY (US) 2012-03-14 EP disclosed
EP-2155886-B1 Cosmetic use of inhibitors of tyrosinase EASTMAN CHEM CO (US) 2012-03-07 EP disclosed
US-20110129430-A1 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS EASTMAN CHEMICAL COMPANY (US) 2011-06-02 US disclosed
EP-2155886-A2 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS Eastman Chemical Company (US) 2010-02-24 EP disclosed
WO-2008153784-A2 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS EASTMAN CHEMICAL COMPANY (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129430-A1 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS TYR, TH, HAAO HSD17B3 50/4885DGKA 710/4885ESR1 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.